Related Experiment Video

Updated: Aug 28, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction

Ruoyu Jia1, Ying Ji2, Dong Sun3

  • 1Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China; Graduate School, Xuzhou Medical University, Xuzhou 221002, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|September 18, 2022
PubMed

Insights

Sacubitril/Valsartan shows significant efficacy in heart failure with preserved ejection fraction (HFpEF). This review highlights its cardiovascular, renal, and metabolic benefits, offering insights for future research and clinical practice.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • Heart failure with preserved ejection fraction (HFpEF) affects nearly half of heart failure patients and is rising.
  • Traditional treatments like ACE inhibitors and ARBs have shown limited efficacy in HFpEF.
  • Sacubitril/Valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), represents a novel therapeutic approach.

Purpose of the Study:

  • To review the latest advancements of Sacubitril/Valsartan in HFpEF.
  • To explore its cardiovascular, renal, and metabolic effects.
  • To discuss the academic consensus on Sacubitril/Valsartan for HFpEF treatment in China.

Main Methods:

  • Literature review of recent studies on Sacubitril/Valsartan.
  • Analysis of cardiovascular, renal, and metabolic outcomes.
  • Synthesis of current evidence and expert consensus.

Main Results:

  • Sacubitril/Valsartan has demonstrated significant efficacy in HFpEF.
  • Evidence supports its benefits across cardiovascular, renal, and metabolic domains.
  • Recent studies are increasingly focusing on HFpEF, moving beyond HFrEF.

Conclusions:

  • Sacubitril/Valsartan is a promising therapeutic option for HFpEF.
  • Further research is warranted to fully elucidate its long-term effects and optimal use.
  • This review provides a foundation for understanding its role and acceptance in China.

Keywords:
ARNIHFpEFHeart failurePharmacological mechanismSacubitril/Valsartan

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
21
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
489
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
459
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
418
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25